Catherine Kolonko

Diabetic patients who received non-invasive shockwave therapy for frozen shoulder had improved range of motion and diminished pain.

For patients with HIV, liver disease is a major cause of morbidity and mortality.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Zepatier is already approved in the United States and Canada for treatment of hepatitis C.

HCV-related deaths continued to rise while deaths from 60 other infectious diseases declined.

Deaths related to liver cancer from hepatitis C virus increase during a time when overall cancer deaths continue to decline.

Expanded federal funding allows Department of Veterans Affairs to fund care for all veterans with hepatitis C.

Zepatier can be used with or without ribavirin and does not require interferon.

Zepatier is approved for the treatment of patients with chronic hepatitis C virus genotypes 1 and 4.

Consuming less dietary cholesterol may reduce mortality or transplantation in women with hepatitis C.

Rapid intervention helps patient with hepatitis C avoid cirrhosis, carcinoma, and end-stage liver disease.

Human pegivirus-2 found only in patients with hepatitis C.

An estimated 500,000 incarcerated people in the US are currently infected with hepatitis C.

Gilead alleged to have priced and marketed Sovaldi to maximize revenue without regard to consequences for patients.

Early treatment found to be cost-effective compared with waiting until liver fibrosis worsens.

Legislators focus on the pricing of sofosbuvir and Harvoni.

One-step test will screen, detect and confirm a hepatitis C virus infection.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Immune mechanisms found to have significant impact on overcoming HCV.

Velpatasvir is a pangenotypic NS5A inhibitor for patients with hepatitis C genotypes 1 through 6 of the virus.

Hepatitis C incidence rate among HIV-positive men who have sex with men grew three-fold from 1991 to 2010.

Drug that targets interaction with RNA does not damage other proteins.